Wells Fargo lowers Arcturus Therapeutics stock price target to $42 on model updates

Wells Fargo lowered its price target on Arcturus Therapeutics (ARCT) to $42.00 while maintaining an Overweight rating, following the biotech's Q2 2025 results. Although the reported net loss of ($0.34) per share was better than one consensus estimate, it significantly missed another, yet Wells Fargo improved its 2025 and 2026 EPS forecasts. The firm noted ARCT's strong cash position of $253.4 million, sufficient through 2028, and maintains a favorable outlook ahead of upcoming cystic fibrosis data, underscoring the stock's high volatility and InvestingPro's assessment of undervaluation.

Analysis

Wells Fargo has adjusted its valuation on Arcturus Therapeutics (ARCT), lowering its price target to $42.00 from $45.00 while reiterating an Overweight rating. This decision follows the company's second-quarter 2025 financial results, which presented a conflicting picture. While the reported net loss of ($0.34) per share was significantly better than a consensus estimate of ($0.89), it also represented a 110.59% negative surprise against a separate, higher expectation of $3.21 EPS. Furthermore, quarterly revenue of $28 million marked a year-over-year decline. Despite these mixed results, Wells Fargo has improved its forward-looking EPS estimates for 2025 and 2026, indicating a more favorable view of future profitability. A key stabilizing factor is Arcturus's robust cash position of $253.4 million, which management confirms is sufficient to fund operations into 2028, significantly de-risking the company's financial runway relative to its $309 million valuation. The analyst's continued positive stance is primarily driven by the upcoming cystic fibrosis data readout, where they anticipate a strong showing based on the targeted patient population and differentiated product profile. The stock's high beta of 2.26 underscores its inherent volatility leading into this key clinical catalyst.

Key Decisions for Investors

• Investors should view Arcturus Therapeutics as a catalyst-driven holding, with the investment thesis heavily dependent on the outcome of the upcoming cystic fibrosis data readout next month.
• The company's strong cash position, providing a funding runway into 2028, substantially mitigates near-term financing risk and provides a crucial buffer against the reported revenue decline and mixed earnings.
• Given the stock's high volatility (beta of 2.26) and conflicting signals between the price target cut and maintained Overweight rating, investors should carefully manage position size and consider the binary risk associated with the clinical trial results.